Skip to main content

Table 1 Baseline characteristics of 82 patients diagnosed with IC in the ICU

From: Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China

  N (%) or P50 (P25,P75) Mortality status (all-cause)
Survived (n = 40) Did not survive (n = 42) Z/χ2/ Fisher’s exact test P
Age (years) 76.0 (65.8, 82.0) 76.0 (61.3, 81.8) 78.0 (67.0, 84.0) −0.673# 0.501
Males 50 (61.0) 26 (65.0) 24 (57.1) 0.532* 0.466
Hospital admission
 Medical ward 28 (34.1) 14 (35.0) 14 (33.3) 0.025* 0.874
 Surgical ward 54 (65.9) 26 (65.0) 28 (66.7)   
Underlying conditions
 Diabetes 27 (32.9) 12 (30.0) 15 (35.7) 0.303* 0.582
 Hypertension 36 (43.9) 14 (35.0) 22 (52.4) 2.513* 0.113
 Chronic cardiac disease 18 (22.0) 7 (17.5) 11 (26.2) 0.903* 0.342
 Chronic liver disease 9 (11.0) 5 (12.5) 4 (9.5) 0.006* 0.938
 Solid tumor 30 (36.6) 15 (37.5) 15 (35.7) 0.028* 0.867
 COPD 2 (2.4) 0 (0.0) 2 (4.8) -Δ 0.494
 Hematological malignancy 5 (6.1) 2 (5.0) 3 (7.1) 0.000* 1.000
 Chronic renal dysfunction 17 (20.7) 4 (10.0) 13 (31.0) 5.473* 0.019
 Surgery 48 (58.5) 25 (62.5) 23 (54.8) 0.505* 0.477
GCS score 11.0 (9.0, 15.0) 11.0 (11.0, 15.0) 10.0 (6.0, 11.0) −4.225# 0.000
Previous treatment
 Antifungal treatment 27 (32.9) 12 (30.0) 15 (35.7) 0.303* 0.582
 Caspofungin 22 (26.8) 11 (27.5) 11 (26.2) 0.018* 0.894
 Fluconazole 39 (47.6) 19 (47.5) 20 (47.6) 0.000* 0.991
 Amphotericin B 2 (2.4) 0 (0.0) 2 (4.8) -Δ 0.494
 Voriconazole 32 (39.0) 18 (45.0) 14 (33.3) 1.172* 0.279
 Previous steroid therapy 25 (30.5) 10 (25.0) 15 (35.7) 1.110* 0.292
 Previous antibiotic therapy 63 (76.8) 31 (77.5) 32 (76.2) 0.020* 0.888
Laboratory data
 P/F ratio 256.1 (188.4, 337.3) 290.5 (241.5, 370.8) 224.0 (130.0, 270.0) −3.553# 0.000
 Anemia (HGB < 70 g/l) 27 (32.9) 10 (25.0) 17 (40.5) 2.222* 0.136
 Neutropenia (< 1 months) 7 (8.5) 2 (5.0) 5 (11.9) 0.523* 0.470
 WBC > 20*109/l 26 (31.7) 11 (27.5) 15 (35.7) 0.638* 0.424
 Temperature > 38 °C 68 (82.9) 31 (77.5) 37 (88.1) 1.624* 0.202
 Hypoproteinemia 81 (98.8) 39 (97.5) 42 (100.0) -Δ 0.488
 MAP, mean (SD) 76.7 (66.5, 90.0) 85.5 (73.3, 94.5) 68.0 (57.0, 78.3) −4.134# 0.000
Previous invasive procedures
 Central venous catheter 13.0 (5.5, 27.0) 13.0 (6.0, 25.5) 14.0 (4.5, 29.5) −0.454# 0.650
 Urinary tract catheter 13.0 (5.0, 27.0) 12.5 (5.0, 24.0) 17.0 (5.5, 35.5) −1.026# 0.305
 Total parenteral nutrition 10.5 (3.8, 21.3) 8.5 (3.3, 15.8) 13.0 (4.5, 27) −1.023# 0.307
 Mechanical ventilation 3.5 (1.0, 10.3) 2.5 (1.0, 9.5) 5.50 (1.0, 15.0) −1.514# 0.130
SOFA score 8.0 (4.0, 11.0) 5.0 (4.0, 8.0) 10.0 (8.5, 14.0) −4.628# 0.000
Outcome (days)
 ICU length of stay 16.0 (4.8, 51.8) 16.0 (5.3, 36.3) 14.5 (3.0, 66.0) −0.223# 0.823
 Hospital length of stay 45.0 (27.8, 81.3) 40.0 (28.0, 98.0) 49.0 (26.5, 81.0) −0.014# 0.989
 Mechanical ventilation 8.5 (1.8, 23.3) 5.0 (1.0, 11.0) 11.5 (3.0, 37.5) −2.461# 0.014
  1. *: Chi-square test; #: rank sum test; Δ: Fisher’s exact test
  2. P50 (P25,P75): the quartile summary is viewed as P25, P50, and P75. For P50, there is a 50% chance that the mean power production will not be reached at any given time